VivoSeq
Infectious Disease

MRSA

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

MRSA is an early-stage landscape with 0 programs across 1 company. The most active players are Nitric BioTherapeutics, Inc.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nitric BioTherapeutics, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Terminated1 · 25%

Clinical Trials

Trial Activity

Retapamulin for Reducing MRSA Nasal Carriage
Completed·UUniversity of California, Irvine·Phase 4·NCT01461668·53 enrolled
MESS-study MRSA Eradication Study Skåne
Completed·—·N/A·NCT01269541·69 enrolled
Retapamulin as a Decolonizing Agent for MRSA
Completed·NNYU Langone Health·Phase 3·NCT03304873·47 enrolled
Reduction of Bacteria in MRSA Positive Ulcers
Terminated·NNitric BioTherapeutics, Inc·Phase 1/2·NCT00771368·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)